HC Wainwright & Co. Reiterates Neutral on RAPT Therapeutics
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Neutral rating on RAPT Therapeutics (NASDAQ:RAPT).

July 23, 2024 | 11:20 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Neutral rating on RAPT Therapeutics. This suggests that the analyst does not foresee significant short-term changes in the stock's performance.
The reiteration of a Neutral rating indicates that the analyst does not expect significant positive or negative changes in the stock's performance in the short term. This is a signal for investors to hold their current positions.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100